Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Blincyto Doubles Survival In TOWER

Executive Summary

The full data that led to Amgen Inc.'s Phase III TOWER study of Blincyto in acute lymphoblastic leukemia being stopped early in February have now been presented and show that treatment with the product nearly doubled overall survival. However, expectations were already high for the product and the data are unlikely to impact sales.

Advertisement

Related Content

More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals
When Will Real World Evidence Be Persuasive? FDA's Temple Offers Perspective
Keeping Track: US FDA Approvals Binge Continues With Dupixent, Ocrevus And Zejula; Two CAR-T Are Under Review
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Amgen gains early US win for BiTE antibody Blincyto

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel